Table 3.
Anti-hyperglycemic agents (AHA), Hydroxychloroquine and associated risk of hypoglycemia during lockdown.
| Sr. No | Anti-diabetic drugs | N (%) | RBG (mg/dl), Mean ± SD |
|---|---|---|---|
| 1 | Metformin + SU | 96 (65.75) | 60.95 ± 7.10 (36–78) |
| 2 | Metformin + SU + TZD | 16 (10.96) | 61.68 ± 3.45 (54–66) |
| 3 | Metformin + SU + DPP-4i | 25 (17.12) | 60.24 ± 5.26 (43–67) |
| 4 | Metformin + SGLT-2 inhibitors | 12 (8.33) | 60.53 ± 8.12 (44–69) |
| 5 | Insulin | 49 (33.56) | 50.75 ± 8.20 (35–67) |
| 6 | Hydroxychloroquine 400 mg OD | 28 (19.17) | 54.82 ± 4.76 (36–61) |
| 7 | Hydroxychloroquine 400 mg BD | 49 (33.56) | 52.95 ± 7.03 (35–67) |
n: Number of subjects; RBG: Random blood glucose; SU: Sulfonylureas; TZD: Thiazolidinediones; DPP-4i: Dipeptidyl peptidase-4 inhibitor; SGLT-2 inhibitors: Sodium-glucose co-transporter-2 inhibitors, OD: Once a day, BD: Twice a day.